✦ LIBER ✦

Cost-effectiveness of a predictive biomarker for bevacizumab responsiveness in the primary treatment of ovarian cancer

✍ Scribed by J. Barnett; A. Alvarez-Secord; D. Cohn; C. Leath; B. Peterson; E. Myers; L. Havrilesky

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost effectiveness of alternative strate

✍ Barnett, Jason C.; Alvarez Secord, Angeles; Cohn, David E.; Leath, Charles A.; M 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 350 KB

Incorporation of Bevacizumab in the Prim

✍ Burger, Robert A.; Brady, Mark F.; Bookman, Michael A.; Fleming, Gini F.; Monk, 📂 Article 📅 2011 🏛 Massachusetts Medical Society 🌐 English ⚖ 690 KB

Is paclitaxel a more cost-effective choi

✍ Kushnir, C.L.; Frick, K.; Zhao, Z.; Giuntoli, R.L. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 101 KB

A cost effective strategy of bevacizumab

✍ J. Chan; T. Herzog; L. Hu; T. Kiet; B. Monk; D. Kapp; X. Yu 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Is maintenance paclitaxel a more cost-ef

✍ Kushnir, C.; Zhao, N.; Frick, K.; Giuntoli, R. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 46 KB

PCN58 BEVACIZUMAB FOR THE TREATMENT OF M

✍ A Fortune-Greeley; P Cornell 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB